Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies - Wikidata - wikimedia - TriplyDB

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies

http://www.wikidata.org/entity/Q33688759

about

Overview of proteomics studies in obstructive sleep apnea Discovery of new biomarkers for malignant mesothelioma Current application of proteomics in biomarker discovery for inflammatory bowel disease Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients Current strategies and findings in clinically relevant post-translational modification-specific proteomics Determination of variation parameters as a crucial step in designing TMT-based clinical proteomics experiments Evaluating the effects of preanalytical variables on the stability of the human plasma proteome Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients Proteogenomic convergence for understanding cancer pathways and networks.The impact of growth hormone on proteomic profiles: a review of mouse and adult human studies.OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.Reverse-polynomial dilution calibration methodology extends lower limit of quantification and reduces relative residual error in targeted peptide measurements in blood plasma.Improving the quality of biomarker discovery research: the right samples and enough of them Targeted proteomics: a bridge between discovery and validation.Cancer biomarker discovery using DNA aptamers.Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?A statistical challenge: developing tests for biomarker utility specific to the intended use.Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.Tools for monitoring system suitability in LC MS/MS centric proteomic experiments.Quantitation with chemical tagging reagents in biomarker studies.Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease.Developing Peripheral Blood Gene Expression-Based Diagnostic Tests for Coronary Artery Disease: a Review.Human proteoforms as new targets for clinical mass spectrometry protein tests.Crucial considerations for pipelines to validate circulating biomarkers for breast cancer.Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications.Mass spectrometry protein tests: ready for prime time (or not).Antigen arrays for profiling autoantibody repertoires.Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: an update.Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Revisiting biomarker discovery by plasma proteomics.Comprehensive Proteome Profiling of Platelet Identified a Protein Profile Predictive of Responses to An Antiplatelet Agent Sarpogrelate.Advances in cell-free protein array methods.Advances in endometrial cancer protein biomarkers for use in the clinic.Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range.

P2860

Q26830581-77884C84-C337-4CA0-8C49-162232C22BC7 Q26849620-E9104DC4-0F0E-48F5-B27D-7E093B47F30E Q28078755-A044C436-0CB8-4BDA-89A3-667D56C7DBDB Q28085015-455E1ED1-A18D-4017-AD96-74375305E177 Q28085402-DA1C021C-ECC0-42D6-97E2-F1B8158D596B Q28544078-4656647A-90C8-4CBC-BDFF-DD5038BC0137 Q30372676-D1C43F1C-4A9F-4A9E-898B-A919FCC1FBBC Q30843287-CCD53E62-F72F-4558-947F-847FA2240D4B Q33555287-68F7092A-8EA0-4FDF-840C-6C1FD1D6C6E9 Q33792433-E0FEF020-B629-4E14-AEFB-755034EA847F Q33857579-420ED854-1B9D-49B9-BCCB-2AE3E1EEA987 Q34475498-8E81C1F1-FC3A-49D4-98D8-14E93A938169 Q34669490-88012CD2-A6E4-4AA0-8E3D-85A7C7D1A5A1 Q35148596-8FA9BCDC-00FD-4CFA-9AE3-C7FF366E87E8 Q35674848-C98DD3AC-0A05-443F-BE5B-0B0A405E291D Q35815142-6454005B-E57E-4ABF-ABD8-C5526799B8F2 Q36430991-308CF435-0D65-4651-B061-2799ADD935DE Q37213295-D4B98103-88D0-4C5D-874F-89724F673AFD Q37696711-78D5285F-BE7A-4B0D-BF6C-185075C5CD88 Q37714579-2D5AF53D-C265-46C1-AA06-611651443676 Q38183147-7A82BA79-8063-4FC3-AC3D-4CBA11626DF2 Q38261241-F0AADBD0-C1B4-4E43-BAC9-AA7686C17806 Q38287636-C5388493-E3DB-4E3A-965D-CC1704B519DD Q38376993-EF1F904F-934E-4B76-BF7B-85765594C337 Q38537439-F7E4F286-E9AC-4D79-9B28-EAA1B14C1AD3 Q38649742-C39FEBB6-7016-4CBF-A183-F7C76E2E272E Q38665032-0EC7F0D5-AC6F-4DDD-8C24-636930EF937F Q38748131-984FE8DE-7AD5-4FCF-97EE-9E213307CF19 Q38799731-49F74CE5-739B-4917-8EE7-71D53AF71A9F Q38812946-165C63F7-0CA4-4BD2-BE39-6FA4137FE78F Q38856893-56598F63-7AB1-4A5E-B760-4274ACAC9C95 Q41173805-5A620C06-416B-416C-B759-EA2235B820BB Q41676452-24AFC326-97DE-45F5-AA20-413F8D84F1E5 Q42687813-16E786A2-6467-4D54-B391-FCB349ADBDC9 Q46844418-C23F0189-367A-4BED-A33E-17F4E5E9CC4D Q47355920-4FEAF6A9-DA06-41BB-8CCE-4F7E609E6E1D Q47417501-5162AF59-ADE4-462F-87EF-6819E9824E38 Q48339070-6D8B20FF-271B-4E64-A2F3-0DCAFD180C7C Q50041836-7E29C339-2360-4E67-BE80-15AFB9E0CD86

P2860

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies

http://www.wikidata.org/entity/Q33688759

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Statistical design for biospec ...... overy and verification studies

@ast

Statistical design for biospec ...... overy and verification studies

@en

type

label

Statistical design for biospec ...... overy and verification studies

@ast

Statistical design for biospec ...... overy and verification studies

@en

prefLabel

Statistical design for biospec ...... overy and verification studies

@ast

Statistical design for biospec ...... overy and verification studies

@en

P1433

Q33688759-D1DB5599-0949-4636-AFAE-69B3BDFF304D

P1476

Q33688759-A9F5260F-5C2C-4BD4-844C-750D0488FF4A

P2093

Q33688759-183096CA-CCBF-4DCC-83C4-287FFFD4280F

Q33688759-1FC182E6-60A4-4306-A916-E7AE13B99F60

Q33688759-218F0158-72FD-46D8-92BD-7277CAE31C3D

Q33688759-3F12D8C1-B548-41B7-BDAF-F0EE985B2EE8

Q33688759-5016760D-7E1C-41EE-91F5-251DEF9AFE9C

Q33688759-65AB6EDD-C73C-4FCA-BF0A-889444E2C930

Q33688759-77955BAC-EAA5-424F-BB5C-DFC9A96F20A5

Q33688759-7BDA2CB4-5EC3-45ED-9323-A36E2D3AC322

Q33688759-7EAA4B49-5312-44C1-9FC4-F1C86F7B0362

Q33688759-8EAEA586-F006-4E97-997C-DCB0123904C8

P2860

Q33688759-02A36667-3679-4DBF-87FC-39E6A5CD38E7

Q33688759-177F10C8-518A-4CD2-9F95-7A0D915F0FE2

Q33688759-1D0983E8-1377-4D7D-92C4-7AF98EE35EAD

Q33688759-21285470-87BB-400F-9190-A49C9BF959A3

Q33688759-279DD940-E8AD-4952-8EC5-1EB8EF002C82

Q33688759-2DA9EC08-7559-4616-978F-72A3FF05E853

Q33688759-3BF9E181-1F6F-4CB3-B89C-36189BFF24A8

Q33688759-3C6D9866-1339-4711-9193-B37BBB070AB2

Q33688759-3EBEDEEF-4877-47ED-9297-FA605A141A3A

Q33688759-53F68CA8-DC46-4363-BBB6-C7D7B8A864A2

P304

Q33688759-13CAA745-156D-4315-AA68-9CED13831654

P31

Q33688759-E0669CCA-5E77-4AD9-AE44-861AAA94BC14

P356

Q33688759-40275217-959E-4E65-89A9-21798FCE4285

P433

Q33688759-7E295D06-75AD-4775-BB55-2116756A8C36

P478

Q33688759-1EA8748D-FE05-42A9-859F-A7181541B3AB

P50

Q33688759-968E1A35-08C9-4010-9601-441257544E64

Q33688759-C5ABA07C-878E-408B-AA86-EBA8DED924A9

P577

Q33688759-444B0795-60EF-4712-A16F-BA4B3487F120

P698

Q33688759-79BC7432-5AAD-4BEE-A823-8A3B11C2CE6B

P921

Q33688759-358F44AE-2407-4525-8B6C-7EE009817571

Q33688759-84647430-265E-44F4-8683-04027DF381BE

P932

Q33688759-59C1B1F9-B791-4C4E-A3EC-E777B04B5CF4

P356

P1433

Journal of Proteome Research

P1476

Statistical design for biospec ...... overy and verification studies

@en

P2093

Ann L Oberg

http://www.w3.org/2001/XMLSchema#string

Christopher R Kinsinger

http://www.w3.org/2001/XMLSchema#string

Daniel C Liebler

http://www.w3.org/2001/XMLSchema#string

Elizabeth Mansfield

http://www.w3.org/2001/XMLSchema#string

Emily S Boja

http://www.w3.org/2001/XMLSchema#string

Grady Barnes

http://www.w3.org/2001/XMLSchema#string

Henry Rodriguez

http://www.w3.org/2001/XMLSchema#string

Ian Wright

http://www.w3.org/2001/XMLSchema#string

Leigh Anderson

http://www.w3.org/2001/XMLSchema#string

Marina Kondratovich

http://www.w3.org/2001/XMLSchema#string

P2860

The human plasma proteome: a nonredundant list developed by combination of four separate sources

The human plasma proteome: history, character, and diagnostic prospects

Proteomics by mass spectrometry: approaches, advances, and applications

Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data.

Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database.

Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry

An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers.

Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Restructuring proteomics through verification

P304

5383-5394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/PR400132J

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

David Ransohoff

P577

2013-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24063748

http://www.w3.org/2001/XMLSchema#string

P921

P932

4039197

http://www.w3.org/2001/XMLSchema#string